Get the Daily Brief
Latest Biotech News
Guardant acquires MetaSight: Shield screening business set to scale
Guardant Health acquired early cancer‑detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, expanding its screening portfolio alongside its...
Ionis halts Alzheimer’s program for people with Down syndrome
Ionis Pharmaceuticals ended development of an Alzheimer’s drug candidate aimed at people with Down syndrome, the company confirmed to Endpoints News. The discontinuation removes a targeted effort...
Japan endorses two iPSC drugs: Regulatory first for cell‑derived therapies
Japan’s regulatory advisory committee recommended conditional approvals for two induced pluripotent stem cell (iPSC)‑derived therapies—Amchepry (raguneprocel) and Reheart—under the country’s...
Insilico and Lilly map 'prompt‑to‑drug' autonomous R&D
Researchers from Insilico Medicine and Eli Lilly published a vision in ACS Central Science outlining a fully autonomous, AI‑driven 'prompt‑to‑drug' pipeline that integrates generative models...
Novartis to sell India unit – keeps R&D and commercial operations
Novartis said it will sell its 70.68% stake in Novartis India Limited to a consortium of private equity firms for about $159 million, while retaining Novartis Healthcare Private Limited, its...
Bioversys reports TB proof‑of‑concept in NEJM: Alpibectir potentiates ethionamide
Bioversys published phase IIa early bactericidal activity data in the New England Journal of Medicine showing that alpibectir (BVL‑GSK098) combined with ethionamide demonstrated clinical...
Grail’s Galleri misses NHS endpoint – shares plunge
The National Health Service trial of Grail’s Galleri multicancer early detection (MCED) test failed to meet its primary endpoint of a statistically significant reduction in stage III–IV cancers....
FDA reopens review of Moderna’s mRNA flu shot – political pressure scrutinized
The FDA reversed an earlier refusal-to-file and agreed to review Moderna’s seasonal mRNA flu vaccine mRNA-1010 after a Type A meeting with the company, setting a PDUFA-style target decision date...
Guardant buys MetaSight, lifts 2026 screening outlook
Guardant Health acquired early cancer-detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, and announced aggressive 2026 guidance for its...
Japan backs two iPSC therapies under conditional approval pathway
Japan’s regulatory advisers recommended conditional, time-limited endorsements for two induced pluripotent stem cell (iPSC) therapies—Amchepry (raguneprocel) and Reheart—paving the way for them to...
FDA sets Dec. 18 decision date for Roche’s oral SERD giredestrant
The U.S. Food and Drug Administration has set a Dec. 18 decision date on Roche’s giredestrant for ER-positive, HER2-negative breast cancer, based on a Phase 3 dataset that showed progression‑free...
Industry leadership churn: Daiichi names John Tsai; CFO hires surge
Daiichi Sankyo appointed John Tsai, former CMO at Novartis and Amgen, to lead global R&D effective April 1 as Ken Takeshita steps down. Tsai’s hiring signals a strategic tilt toward experienced,...
Ionis halts Alzheimer’s candidate for people with Down syndrome
Ionis Pharmaceuticals has discontinued development of an early investigational Alzheimer’s candidate intended for people with Down syndrome, the company confirmed to industry press. The program’s...
Disordered lipid nanoparticles boost delivery efficiency – new evidence
New experimental work shows that a subpopulation of amorphous, disorganized lipid nanoparticles (LNPs) releases RNA cargo more efficiently inside cells than highly organized particles. A...
Structural control of bacterial DNA synthesis reveals new antimicrobial target
Researchers revealed structural mechanisms bacteria use to control ribonucleotide reductase (RNR) expression, identifying the transcriptional regulator NrdR as a bacteria‑specific node for...
Insilico-Lilly blueprint and synthetic data push AI deeper into drug R&D
Insilico Medicine and Eli Lilly published a vision for a fully autonomous “prompt‑to‑drug” pipeline that integrates generative AI across design, synthesis and testing—outlining technical and...
Grail’s Galleri misses UK goal – shares collapse
Grail reported that its large NHS-Galleri multicancer early detection (MCED) trial did not meet the study’s primary endpoint, prompting a dramatic market reaction. The company disclosed top-line...
FDA reverses course on Moderna’s mRNA flu shot
The FDA rescinded an initial Refusal to File and agreed to review Moderna’s seasonal mRNA influenza vaccine mRNA‑1010 after a Type A meeting, setting a PDUFA target date in August. Moderna...
Guardant accelerates screening push, buys MetaSight
Guardant Health signaled aggressive expansion of its screening business and disclosed the acquisition of early cancer detection startup MetaSight Diagnostics for $59 million upfront plus up to $90...
Danaher to acquire Masimo; diagnostic contractors tapped by CDC
In industry briefings, Danaher disclosed a definitive agreement to acquire Masimo for roughly $9.9 billion, consolidating patient‑monitoring and oximetry technologies into Danaher’s diagnostics...